TEC

DRUG2 trials

Sponsors

University of Magdeburg, Shanghai Zhongshan Hospital

Conditions

Colorectal NeoplasmsNon-Hodgkin's Lymphoma

Phase 1

Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma

University of MagdeburgNon-Hodgkin's Lymphoma

Start: 2004-06-30End: 2010-06-30Target: 30Updated: 2006-10-06

Phase 2

Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC

Shanghai Zhongshan HospitalColorectal Neoplasms

Start: 2021-02-01End: 2024-02-28Updated: 2023-03-28

Related Papers

Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study

Nature Communications2024-08-2318 citations

Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: A phase II, single-arm study.

Journal of Clinical Oncology2023-01-241 citations

Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: Preliminary findings of a phase II, single-arm study.

Journal of Clinical Oncology2022-06-012 citations